Polymeric biomaterials derived from phenolic monomers and their medical uses
US-2016376401-A1 · Dec 29, 2016 · US
US11383003B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11383003-B2 |
| Application number | US-202016742404-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 14, 2020 |
| Priority date | Dec 27, 2012 |
| Publication date | Jul 12, 2022 |
| Grant date | Jul 12, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Farnesol analogs, along with their related products (e.g., treatment compositions, wipes, absorbent articles, etc.) and their methods of formation, are provided. The farnesol analog includes a hydrophilic end group (e.g., a hydroxyl end group or a carboxylic acid end group) attached to farnesol via a covalent linkage (e.g., an ester group or an ether group).
Opening claim text (preview).
What is claimed is: 1. A web comprising a plurality of fibers, wherein the web comprises a treatment composition, the treatment composition comprising a farnesol analog comprising a hydrophilic end group attached to farnesol via a covalent linkage, wherein the hydrophilic end group defines a hydroxyl end group or a carboxylic acid end group, and wherein the covalent linkage comprises an ester group or an ether group. 2. The web according to claim 1 , wherein the covalent linkage comprises at least one ester group. 3. The web according to claim 2 , having the structure: where n is an integer from 1 to about 8, or its deprotonated salt. 4. The web according to claim 3 , wherein n is 2, 3, or 4. 5. The web according to claim 2 , wherein the hydrophilic end group comprises at least two ester groups. 6. The web according to claim 5 , having the structure: where n is an integer from 1 to about 8; and m is an integer from 1 to about 8. 7. The web according to claim 6 , wherein n is 2, 3, or 4; and wherein m is 2, 3, or 4. 8. The web according to claim 1 , wherein the covalent linkage comprises an ether group, and wherein the hydrophilic end group defines a hydroxyl end group. 9. The web according to claim 8 , having the structure: where n is an integer from 1 to about 8. 10. The web according to claim 9 , wherein n is 2, 3, or 4. 11. The web according to claim 8 , having the structure: where n is an integer that is 1 to about 100. 12. The web according to claim 8 , wherein the farnesol analog comprises a monosaccharide covalently attached to the farnesol via an ether linkage. 13. The web according to claim 12 , having the structure: 14. The web according to claim 1 , wherein the farnesol analog has a solubility in water that is 10 grams per 100 grams of water or greater. 15. A wipe comprising the web according to claim 1 . 16. An absorbent article comprising: a liquid impermeable outer cover; a liquid permeable bodyside liner, wherein the bodyside liner comprises the web according to claim 1 ; an absorbent body disposed between the outer cover and bodyside liner. 17. A method of forming a web coated with a treatment composition, comprising forming a treatment composition comprising a farnesol analog that is soluble in water from a farnesol molecule having a hydroxyl group, the method comprising: covalently attaching a hydrophilic end group to the farnesol molecule via reaction with its hydroxyl group to form a covalent linkage, wherein the hydrophilic end group defines a hydroxyl end group or a carboxylic acid end group, and wherein the covalent linkage comprises an ester group or an ether group; and applying the treatment composition to the web. 18. The method as in claim 17 , wherein the covalent linkage comprises an ester group formed via an esterification reaction between the hydroxyl group of the farnesol molecule and a carboxylic acid functional molecule. 19. The method as in claim 18 , wherein the carboxylic acid functional molecule is a dicarboxylic acid such that the hydrophilic end group defines a carboxylic acid end group upon reaction of the dicarboxylic acid with the hydroxyl group of the farnesol molecule. 20. The method as in claim 19 , further comprising: reacting the carboxylic acid end group with a glycol via a second esterification reaction to form a farnesol analog having a hydroxyl group covalently attached via two ester linkages. 21. The method as in claim 20 , wherein the glycol is selected from the group consisting of ethylene glycol, propylene glycol, and butane-1,4-diol. 22. The method as in claim 17 , wherein the covalent linkage comprises an ether group formed by reacting farnesol with an alcohol via a dehydration reaction to form the ether group. 23. The method as in claim 22 , wherein the alcohol is a glycol selected from the group consisting of ethylene glycol, propylene glycol, and butane-1,4-diol. 24. The method as in claim 22 , wherein the hydrophilic end group comprises a sugar.
Monosaccharides · CPC title
Acyclic alcohols with carbon-to-carbon double bonds · CPC title
Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom · CPC title
Additives, e.g. for odour, disinfectant or pH control · CPC title
Succinic acid esters · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.